This study is researching a treatment called BMS-986353 (also known as Zolacabtagene-Autoleucel or Zola-cel) for people with a condition called Systemic Sclerosis (SSc). SSc is a disease that causes thickening and hardening of the skin. Some SSc patients also have Interstitial Lung Disease (ILD), which affects the lungs.

Participants in this study will either continue their usual treatment or receive the new treatment if their condition worsens. To join, participants must meet certain conditions, like having specific antibodies in their blood and lung disease confirmed by a special scan. They must also have tried other medicines for at least 6 months without success.

Some people cannot participate, like those needing oxygen therapy or with other serious lung problems. The study aims to see if the new treatment is better and safer than the current standard care.

• The study involves comparing new treatment with current treatment.
• Participants may switch to new treatment if their condition worsens.
• Participants must meet specific health criteria to join.